Research ArticleOpen AccessGoogle Scholar indexed
Evolution of Biochemical Effects of Byetta<sup>®</sup> in Type 2 Diabetics with Cardiovascular Risk
Pharmaceutical Care Research at the University of Granada, Granada, Spain;
Health Center Mariano Yago, Yecla, Murcia, Spain;
Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain
Infectious Internal Medicine of the Hospital University Virgen de la Arrixaca, Murcia, Spain.
Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain;
Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain;
- 1 Pharmaceutical Care Research at the University of Granada, Granada, Spain;
- 2 Health Center Mariano Yago, Yecla, Murcia, Spain;
- 3 Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain
- 4 Infectious Internal Medicine of the Hospital University Virgen de la Arrixaca, Murcia, Spain.
- 5 Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain;
- 6 Endocrinology and Nutrition Service of the Hospital University Virgen de la Arrixaca, Murcia, Spain;
Pharmacology & Pharmacy·Volume 04 (2013)·Pages 679–683·Published 6 December 2013·DOI10.4236/pp.2013.49094
Copy link · social · email
Abstract
The objective of this study was to examine longitudinally the effects of exenatide on different physical and biochemical markers, evaluated in adult type 2 diabetic patients with cardiovascular risk. Data were recorded from 10 patients who attended the outpatient primary care health center Mariano Iago Yecla, Murcia province, Spain in the period of December 2009 to October 2011 and who were treated with Byetta ® . Differences were statistically significant (p < 0.05) in HbA 1c from the third month of treatment, and trends of decrease in body weight from the third week of treatment. There was a significant and better glycemic control. Overall effect was interpreted as a sensitizer drug of the parameters evaluated. Randomized studies are recommended with a minimum follow - up of 2 years, to see if the results are maintained over time.
KeywordsDiabetes Mellitus Type 2ExenatideCardiovascular Risk
- National Health Service (NHS), “Exenatide,” New Drug Evaluation, Vol. 84, 2007.
- Andalusian Center for Drug Information (CADIMA), “Exenatide (INN),” New Therapeutics, 2009, Sheet 2.
- F. Campoamor, “Exenatide in Type 2 Diabetes Mellitus,” Drug Evaluation Committee, Balearic Islands, 2008.
- F. Verzegnassi and M. Chinelle, “Exenatide in Type 2 Diabetes,” Lancet, Vol. 376, No. 9746, 2010, pp. 1052-1053. http://dx.doi.org/10.1016/S0140-6736(10)61485-7
- A. Peters, “Incretin-Based Therapies: Review of Current Clinical Trial Data,” American Journal of Medicine, Vol. 123, No. 3, 2010, pp. S28-S37. http://dx.doi.org/10.1016/j.amjmed.2009.12.007
- E. Wajcberg and A. Tavari, “Exenatide: Clinical Aspects of the First Incretin Mimetic for the Treatment, of Type 2 Diabetes Mellitus,” Expert Opin Pharmacother, Vol. 10, No. 1, 2009, pp. 135-142. http://dx.doi.org/10.1517/14656560802611832
- J. B. Segal, S. M. Dy, E. A. Millman, R. Herbert, E. B. Bass and A. Wu, “Diffusion Into Use of Exenatide for Glucose Control in Diabetes Mellitus: A Retrospective Cohort Study of a New Therapy,” Therapies in Clinical, Vol. 29, No. 8, 2007, pp. 1784-1794. http://dx.doi.org/10.1016/j.clinthera.2007.08.021
- J. Philippe, “Role and Indication of GLP-1 Analogues in the Treatment of Type 2 Diabetes,” Revue Médicale Suisse, Vol. 5, No. 206, 2009, pp. 1260-1262, 1264-1265.
- H. Reuter and E. Erdmann, “Exenatide—An Incretin-Mimetic Agent for the Treatment of Type 2 Diabetes Mellitus,” Deutsche Medizinische Wochenschrift, Vol. 132, No. 11, 2007, pp. 571-574. http://dx.doi.org/10.1055/s-2007-970380
- D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, et al., “Management of Hyperglycaemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 29, No. 8, 2006, pp. 1963-1972. http://dx.doi.org/10.2337/dc06-9912
- G. Schernthaner, A. H. Barnett, D. J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, et al., “Is the ADA/EASD Algorithm for the Management of Type 2 Diabetes (January 2009) Based on Evidence or Opinion? A Critical Analysis,” Diabetologia, Vol. 53, No. 7, 2010, pp. 1258-1269. http://dx.doi.org/10.1007/s00125-010-1702-3
- German Diabetes Association, S. Matthaei, R. Bierwirth, A. Fritsche, B. Gallwitz, H. U. Haring, et al., “Medical Treatment of Type Antihyperglycaemic 2 Diabetes Mellitus: Update of the Evidence-Based Guideline of the German Diabetes Association,” Experimental and Clinical Endocrinology & Diabetes, Vol. 117, 2009, pp. 522-557.